Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Smit

Showing results (631-640 of 692) with videos related to

Pageof 70
Sort By:
Nature Communications|May 28, 2025
TEIPP-vaccination in checkpoint-resistant non-small cell lung cancer: a first-in-human phase I/II dose-escalation studyMitchell Emmers, Marij J P Welters, Michelle V Dietz, et al.
Frontiers in Immunology|September 11, 2024
mRNA-1273 vaccination induces polyfunctional memory CD4 and CD8 T cell responses in patients with solid cancers undergoing immunotherapy or/and chemotherapyAnastasia Gangaev, Yannick van Sleen, Nicole Brandhorst, et al.
Trials|June 10, 2024
Investigating non-inferiority of internet-delivered versus face-to-face cognitive behavioural therapy for insomnia (CBT-I): a randomised controlled trial (iSleep well)F Benz, L Grolig, S Hannibal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 22, 2019
Predicting response to cancer immunotherapy using noninvasive radiomic biomarkersS Trebeschi, S G Drago, N J Birkbak, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 23, 2015
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF CohortOliver Gautschi, Julie Milia, Bastien Cabarrou, et al.
British Journal of Cancer|February 27, 2015
DNA hypermethylation analysis in sputum for the diagnosis of lung cancer: training validation set approachA J Hubers, D A M Heideman, S A Burgers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2015
Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohortJulien Mazières, Gérard Zalcman, Lucio Crinò, et al.
The New England Journal of Medicine|April 15, 2026
First-Line Zongertinib in Advanced <i>HER2</i>-Mutant Non-Small-Cell Lung CancerJohn V Heymach, Noboru Yamamoto, Nicolas Girard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2017
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II TrialDong-Wan Kim, Marcello Tiseo, Myung-Ju Ahn, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 28, 2003
Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS studyPaul Verboom, Harm van Tinteren, Otto S Hoekstra, et al.
Pageof 70

Showing results (631-640 of 692) with videos related to

Sort By:
Pageof 70
Nature Communications|May 28, 2025
TEIPP-vaccination in checkpoint-resistant non-small cell lung cancer: a first-in-human phase I/II dose-escalation studyMitchell Emmers, Marij J P Welters, Michelle V Dietz, et al.
Frontiers in Immunology|September 11, 2024
mRNA-1273 vaccination induces polyfunctional memory CD4 and CD8 T cell responses in patients with solid cancers undergoing immunotherapy or/and chemotherapyAnastasia Gangaev, Yannick van Sleen, Nicole Brandhorst, et al.
Trials|June 10, 2024
Investigating non-inferiority of internet-delivered versus face-to-face cognitive behavioural therapy for insomnia (CBT-I): a randomised controlled trial (iSleep well)F Benz, L Grolig, S Hannibal, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 22, 2019
Predicting response to cancer immunotherapy using noninvasive radiomic biomarkersS Trebeschi, S G Drago, N J Birkbak, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 23, 2015
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF CohortOliver Gautschi, Julie Milia, Bastien Cabarrou, et al.
British Journal of Cancer|February 27, 2015
DNA hypermethylation analysis in sputum for the diagnosis of lung cancer: training validation set approachA J Hubers, D A M Heideman, S A Burgers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2015
Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohortJulien Mazières, Gérard Zalcman, Lucio Crinò, et al.
The New England Journal of Medicine|April 15, 2026
First-Line Zongertinib in Advanced <i>HER2</i>-Mutant Non-Small-Cell Lung CancerJohn V Heymach, Noboru Yamamoto, Nicolas Girard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2017
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II TrialDong-Wan Kim, Marcello Tiseo, Myung-Ju Ahn, et al.
European Journal of Nuclear Medicine and Molecular Imaging|October 28, 2003
Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS studyPaul Verboom, Harm van Tinteren, Otto S Hoekstra, et al.
Pageof 70